超演教育
20人以下
公司优势
20,861+ 岗位更新等你来订阅
一键订阅最新的岗位，每周送达
🎉恭喜你，订阅成功
继续订阅您可以在邮箱中随时取消订阅
长沙市长房物业管理有限公司是长沙房产(集团)有限公司的下属企业。
北京圣博润高新技术股份有限公司是一家专注于网络安全技术研究、产品研发和安全服务的高新技术企业，注册资金11293.402万元。自2000年成立以来，推出安全防护、安全检测与审计、安全管理、工控安全四大类20余款网络与信息安全产品，其中堡垒主机产品连续五年市场占有率第一。公司是专业的等级保护咨询服务提供商，为数百家行业客户提供专业服务。
圣博润于2009年在新三板挂牌，是中国网络安全五十强企业，2017年新三板创新层企业、2016年新三板十大最具投资价值企业和2016中关村TOP100高成长企业。公司承担科技部、工信部、北京市科委等多项国家和地方信息安全课题研究和专项任务，是国家网络与信息安全信息通报机制技术支持单位，承担北京奥运会、杭州G20峰会、“一带一路”国际合作高峰论坛等重大活动的网络安全保障任务。
公司客户涵盖政府和央企，包括50个国家部委、数十家金融机构及三十多家中央企业。
近年来，公司加大新兴网络安全领域投入，在工控安全、工业互联网安全、移动安全等领域推出系列创新产品，保持技术领先。
秉持“抱圣贤之思，怀博学之志，尽润泽之力”的理念，圣博润致力于为用户提供专业的网络安全咨询与整体解决方案，与用户和合作伙伴共建网络安全未来。
大连润泽汽车销售服务有限公司是大连汽贸集团旗下的长安高端系列UNI品牌专属4S店。店内设施齐全，工作环境优良，提供定期带薪休假，并为正式员工缴纳五险一金。
Introduction of Immunowake Biopharmaceutical Co., Ltd
Immunowake is a global biotech company dedicated to developing and commercializing novel bispecific antibodies for tumor treatment. The company focuses on antibody activation of the immune system, improving the tumor microenvironment, and treating solid tumors. Immunowake aims to develop blockbuster drugs that can compete with those from major Western pharmaceutical companies to address unmet clinical needs. The company has completed its Series A financing. The U.S. R&D center is located in Birmingham, while the R&D center in China is based in Shanghai Zhangjiang Pharmaceutical Valley. In the future, Shanghai will serve as the global R&D hub for Immunowake.
Dr. Xiaoyun Wu, the founder of Immunowake, is a seasoned expert and serial entrepreneur in the field of tumor immunotherapy. With over three decades of work and study experience in the United States, Dr. Wu is an accomplished entrepreneur with strong academic credentials and entrepreneurial expertise. At the end of 2021, Dr. Wu led the core team, research achievements, and technology platforms back to China, initiating a new chapter for Chinese cancer drugs in the global market. Currently, two immunotherapeutic bispecific antibodies are actively preparing for IND application materials, with plans for dual Sino-US submissions next year. Through the collective efforts of the Immunowake team, we aim to contribute to the internationalization of Chinese new drugs.